Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Research Coverage on Small and Micro-Cap Companies

Equity Bottom-Up

<ul><li>On September 22, 2025, Imunon, Inc. (IMNN) announced the presentation of new translational data from the company's Phase 2 OVATION 2 trial of IMNN-001 in patients with newly diagnosed advanced ovarian cancer.</li><li>The results were presented at the American Association for Cancer Research (AACR) Special Conference in Cancer Research: Advances in Ovarian Cancer Research.</li><li>The data showed that there was a positive shift in the tumor microenvironment (TME) through decreased immunosuppressive cells (IDO+, PDL1+, Treg, CD4+) and increased immunostimulatory cells (CD8+, myeloid dendritic cells) in a majority of the patients' post-treatment.</li></ul>

On September 22, 2025, Imunon, Inc. (IMNN) announced the presentation of new translational data from the company's Phase 2 OVATION 2 trial of IMNN-001 in patients with newly diagnosed advanced ovarian cancer.The results were presented at the American Association for Cancer Research (AACR) Special Conference in Cancer Research: Advances in Ovarian Cancer Research.The data showed that there was a positive shift in the tumor microenvironment (TME) through decreased immunosuppressive cells (IDO+, PDL1+, Treg, CD4+) and increased immunostimulatory cells (CD8+, myeloid dendritic cells) in a majority of the patients' post-treatment.

IMNN: OVATION 2 Translational Data Shows IMNN-001 Alters Tumor Microenvironment 